2. Academic Validation
  3. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

  • Cancer Cell. 2015 Sep 14;28(3):384-98. doi: 10.1016/j.ccell.2015.08.002.
Sheng-Bin Peng 1,  James R Henry 2,  Michael D Kaufman 3,  Wei-Ping Lu 3,  Bryan D Smith 3,  Subha Vogeti 3,  Thomas J Rutkoski 3,  Scott Wise 3,  Lawrence Chun 4,  Youyan Zhang 2,  Robert D Van Horn 2,  Tinggui Yin 2,  Xiaoyi Zhang 2,  Vipin Yadav 2,  Shih-Hsun Chen 2,  Xueqian Gong 2,  Xiwen Ma 2,  Yue Webster 2,  Sean Buchanan 2,  Igor Mochalkin 2,  Lysiane Huber 2,  Lisa Kays 2,  Gregory P Donoho 2,  Jennie Walgren 2,  Denis McCann 2,  Phenil Patel 2,  Ilaria Conti 2,  Gregory D Plowman 2,  James J Starling 2,  Daniel L Flynn 3
Affiliations

Affiliations

  • 1 Eli Lilly and Company, Indianapolis, IN 46285, USA. Electronic address: peng_sheng-bin@lilly.com.
  • 2 Eli Lilly and Company, Indianapolis, IN 46285, USA.
  • 3 Deciphera Pharmaceuticals, LLC, Lawrence, KS 66044, USA.
  • 4 Emerald Biostructures, Bainbridge Island, WA 98110, USA.
PMID: 26343583 DOI: 10.1016/j.ccell.2015.08.002
Abstract

LY3009120 is a pan-RAF and Raf dimer inhibitor that inhibits all Raf isoforms and occupies both protomers in Raf dimers. Biochemical and cellular analyses revealed that LY3009120 inhibits ARAF, BRaf, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRaf activities. LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers. Further analyses demonstrated that LY3009120 also inhibits various forms of Raf dimers including BRaf or CRAF homodimers. Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRaf mutation.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验，部分功能也使用 Cookies 帮助我们更好地理解您的需求，为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问，请阅读我们的《隐私声明》。

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z